All In Biotech

NDA 018261 · Ph Health

Pitocin

Oxytocin · Injection · Oxytocic

Last checked: Nov 19, 2026Latest source record: May 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

Nov 19, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

722

71 Phase 3, 51 recruiting

FAERS reports

3,047

2,695 serious, 155 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.

What it is approved for

From the label in effect May 6, 2026.

INDICATIONS AND USAGE IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • PITOCIN · OXYTOCIN 100USP UNITS/10ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • PITOCIN · OXYTOCIN 500USP UNITS/50ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription
  • PITOCIN · OXYTOCIN 10USP UNITS/ML (10USP UNITS/ML) · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxytocin" as an intervention, any sponsor and status, largest first.

All 722 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy456
  • maternal exposure during pregnancy441
  • drug ineffective402
  • exposure during pregnancy366
  • premature baby209
  • hypotension196
  • off label use191
  • premature delivery163
  • postpartum haemorrhage155
  • drug exposure during pregnancy143
  • maternal exposure during delivery137
  • caesarean section105

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200533
200661
200744
200871
200956
201087
201175
201279
2013104
2014128
2015128
2016196
2017149
2018182
2019144
2020213
2021200
2022237
2023298
2024203
2025173
2026144

Recalls

1 FDA enforcement reports for this application.

  • Jun 5, 2012 · Class III · Terminated

    Labeling: Label Mix-up: Pitocin storage conditions should be labeled, "Store between 20¿ to 25¿C (68¿ to 77¿F)". Pitocin lot 225867 and part of Pitocin lot 231423 were labeled, "Store between 20¿ to 25¿C (28¿ to 77¿F)".

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,040 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.